Clinical research for the development of predictive biomarker useful for individualized radiotherapy in the treatment of lung cancer

• Project/Area Number: 26461896
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Kitasato University
• Principal Investigator: Hayakawa Kazushige 北里大学, 医学部, 教授 (70114189)
• Co-Investigator(Kenkyū-buntansha): 三藤 久 北里大学, 看護学部, 准教授 (40260856) ; 蒋 世旭 北里大学, 医学部, 准教授 (70276153)
• Co-Investigator(Renkei-kenkyūsha): MASUDA Noriyuki 北里大学, 医学部, 教授 (70145465)
• Project Period (FY): 2014-04-01 – 2017-03-31
• Project Status: Completed (Fiscal Year 2016)
• Budget Amount: ¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000); Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000); Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2014: ¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
• Keywords: 肺癌 / 放射線治療 / バイオマーカー / 効果予測 / 個別化医療 / 分子標的 / 非小細胞肺癌 / 化学放射線療法 / EGFR遺伝子変異 / EGFRチロシンキナーゼ阻害薬 / 放射線感受性 / 肺腺癌 / Vimentin / 予後因子 / 放射線反応性

Outline of Final Research Achievements

In adenocarcinoma of the lung, vimentin expression is prevalent and markedly up-regulated in micropapllary component (MPC), which might reflect the biological essence of poorer differentiation or dedifferentiation of MPC, and this might have a role in the acquisition and increase of invasiveness and consequent more malignant nature of MPC. In the 64 patients with stage III non-small cell lung cancer (NSCLC), the progression-free survival (PFS) was significantly shorter, and the overall survival (OS) was longer (6.3 vs. 9.5 months, p < .001, PFS, 37.1 vs. 21.1 months, p = 0.26, OS). Distant metastasis happened more frequently in the mutant EGFR than in the wild-type EGFR. In 39 patients received concurrent chemoradiotherapy with a humanized IgG1 monoclonal anti-EGFR antibody (nimotuzumab), the PFS was significantly better for patients with Sq than for those with Non-Sq. The low in field relapse rates may be attributed to the radio-sensitizing effect of anti-EGFR antibody.

Research Products

• [Journal Article] Clinical outcomes of stage I and IIA non-small cell lung cancer patients treated with stereotactic body radiotherapy using a real-time tumor-tracking radiotherapy system. (2017)
  • Author(s): Katoh N, Soda I, Tamamura H, Takahashi S, Uchinami Y, Ishiyama H, Ota K, Inoue T, Onimaru R, Shibuya K, Hayakawa K, Shirato H.
  • Journal Title: Radiation Oncology Volume: 12 Issue: 1 Pages: 1-10
  • DOI: 10.1186/s13014-016-0742-3
  • NAID: 120006498161
  • Peer Reviewed / Open Access
• [Journal Article] Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to the EGFR mutation status. (2017)
  • Author(s): Ishihara M, Igawa S, Sasaki J, Otani S, Katagiri M, Soda I, Isiyama H, Hayakawa K, Masuda N
  • Journal Title: Oncol Lett Volume: 印刷中
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. (2015)
  • Author(s): Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K, Shioyama Y, Onimaru R, Kozuka T, Kunieda E, Saito T, Nakagawa K, Hareyama M, Takai Y, Hayakawa K, Mitsuhashi N, Ishikura S.
  • Journal Title: Int J Radiat Oncol Biol Phys. Volume: 93 Issue: 5 Pages: 989-96
  • DOI: 10.1016/j.ijrobp.2015.07.2278
  • Peer Reviewed / Open Access
• [Journal Article] Prevalent and up-regulated vimentin expression in micropapillary components of lung adenocarcinomas and its adverse prognostic significance (2015)
  • Author(s): Nakashima H, Jiang SX, Sato Y, Hoshi K, Matsumoto T, Nagashio R, Kobayashi M, Matsuo Y, Shiomi K, Hayakawa K, Saegusa M, Satoh Y
  • Journal Title: Pathol Int Volume: 65 Issue: 4 Pages: 183-192
  • DOI: 10.1111/pin.12257
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Presentation] MA06.11 PHASE II STUDY OF NIMOTUZUMAB+CONCURRENT CHEMORADIOTHERAPY(CRT)FOR STAGEⅢMON-SMALL CELL LUNG CANCER(NSCLC):5-YEAR FOLLOW-UP RESULTS (2016)
  • Author(s): 早川 和重
  • Organizer: 第17回世界肺癌学会議(WCLC 2016)(IASLC 2016)
  • Place of Presentation: オーストリア / ウィーン
  • Year and Date: 2016-12-04
  • Int'l Joint Research
• [Book] Stereotactic Body Radiation Therapy: Principles and Practices (2015)
  • Author(s): Kazushige Hayakawa, Nagata Y(ed.)
  • Total Pages: 254
  • Publisher: Springer